Dong-A ST Files for Marketing Approval of Stiren Q Tablet for Acute/Chronic Gastritis, Phase 3 Trial Shows Non-Inferiority
Dong-A ST has filed for domestic marketing approval of Stiren Q tablet, an improved formulation of its flagship gastritis treatment Stiren with enhanced dosing convenience.
The Phase 3 trial demonstrated non-inferiority compared to existing Stiren tablet, and the once-daily dosing is expected to improve patient compliance.
If approved and reimbursed, the new drug could strengthen the gastritis treatment portfolio and contribute to sales growth.
[AI Summary]Dong-A Socio Holdings' subsidiary Dong-A ST applied for marketing approval of Stiren Q tablet. Phase 3 results showed non-inferiority and safety, but final approval is uncertain. Approval could enhance market competitiveness via once-daily dosing, positively impacting shareholder value.
KOSPI Filing Information
Major Management Matters Related to Investment Decision (Major Management Matters of Subsidiary)